» Articles » PMID: 20661220

Minichromosome Maintenance Proteins 2, 3 and 7 in Medulloblastoma: Overexpression and Involvement in Regulation of Cell Migration and Invasion

Overview
Journal Oncogene
Date 2010 Jul 28
PMID 20661220
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

Minichromosome maintenance (MCM) proteins 2-7 are important in DNA replication licensing. Functional roles beyond licensing are speculated. In addition, significances in medulloblastoma (MB) remain unclear. In this study, we showed the frequent deregulation of MCM2 and MCM3 expression in 7 MB cell lines and 31 clinical samples. Moreover, DAOY and ONS76 and the clinical samples expressed elevated MCM7 transcripts with genomic gain of the gene. Immunopositivity restricted to tumor cells was found in 41, 37 and 53 out of 73 MB cases for MCM2, MCM3 and MCM7, respectively. High-MCM3 expression was associated with poor prognosis. Knockdowns of these MCMs significantly inhibited anchorage-dependent and -independent MB cell growth. The inhibition of MCM3 expression by small interfering RNA knockdown was related to G1 arrest with reduced cyclin A expression, whereas the MCM2- and MCM7-knocked-down cells arrested at G2/M with increased cyclin A expression. Interestingly, we demonstrated the links of these MCMs with cell migration and invasion using wound-healing and Transwell migration/invasion assays. Exogenous overexpression of MCM2, MCM3 and MCM7 increased anchorage-independent cell growth, and also cell migration and invasion capabilities in MB cells. The knockdown reduced the number of filopodial cells and the cells with intense stress fibers by blocking cdc42 and Rho activation. Taken together, deregulation of MCM2, MCM3 and MCM7 expression might be involved in MB tumorigenesis and we revealed undefined roles of these MCMs in control of MB cell migration and invasion.

Citing Articles

The prognostic and immunological role of MCM3 in pan-cancer and validation of prognosis in a clinical lower-grade glioma cohort.

Huang Q, Jiang Q, Tan J, Nong R, Yan J, Yang X Front Pharmacol. 2024; 15:1390615.

PMID: 38698811 PMC: 11063780. DOI: 10.3389/fphar.2024.1390615.


Heterogeneous Expression Patterns of the Minichromosome Maintenance Complex Members in Retinoblastoma Unveil Its Clinical Significance.

Tang J, Liu Y, Zhang Z, Ren Y, Ma Y, Wang Y Invest Ophthalmol Vis Sci. 2024; 65(1):31.

PMID: 38231525 PMC: 10795548. DOI: 10.1167/iovs.65.1.31.


Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development.

Lu T, Li C, Gong Y, Hou F, Chen C World J Gastrointest Oncol. 2023; 15(10):1717-1738.

PMID: 37969406 PMC: 10631436. DOI: 10.4251/wjgo.v15.i10.1717.


MCM4 acts as a biomarker for LUAD prognosis.

Tan Y, Ding L, Li G J Cell Mol Med. 2023; 27(21):3354-3362.

PMID: 37817427 PMC: 10623528. DOI: 10.1111/jcmm.17819.


O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N-methyladenosine-dependent manner.

Yang Y, Yan Y, Yin J, Tang N, Wang K, Huang L Signal Transduct Target Ther. 2023; 8(1):63.

PMID: 36765030 PMC: 9918532. DOI: 10.1038/s41392-023-01316-8.